Currently, advancements in technology, such as Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET), have enhanced the accuracy of oncological assessments and mitigated the surgical complications associated with malnutrition risk (57, 58). This evidence concerns the gene FOLH1 and malnutrition.